Roles of fibroblast growth factors in the treatment of diabetes.
Clinical trials
Fibroblast growth factors
Metabolic disorders
Treatment
Type 1 diabetes
Type 2 diabetes
Journal
World journal of diabetes
ISSN: 1948-9358
Titre abrégé: World J Diabetes
Pays: United States
ID NLM: 101547524
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
received:
18
11
2023
revised:
16
12
2023
accepted:
25
01
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
9
4
2024
Statut:
ppublish
Résumé
Diabetes affects about 422 million people worldwide, causing 1.5 million deaths each year. However, the incidence of diabetes is increasing, including several types of diabetes. Type 1 diabetes (5%-10% of diabetic cases) and type 2 diabetes (90%-95% of diabetic cases) are the main types of diabetes in the clinic. Accumulating evidence shows that the fibroblast growth factor (FGF) family plays important roles in many metabolic disorders, including type 1 and type 2 diabetes. FGF consists of 23 family members (FGF-1-23) in humans. Here, we review current findings of FGFs in the treatment of diabetes and management of diabetic complications. Some FGFs (
Identifiants
pubmed: 38591079
doi: 10.4239/wjd.v15.i3.392
pmc: PMC10999039
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
392-402Informations de copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors have no conflicts of interest to declare.